Related Experiment Video
Updated: Jan 1, 2026

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
Published on: January 29, 2014
Complement fragments are biomarkers of antibody-mediated endothelial injury
Erik Stites1, Brandon Renner1, Jennifer Laskowski1
1Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA.
Insights
Soluble complement fragments like C4a and Ba in plasma may serve as non-invasive biomarkers for detecting antibody-mediated rejection (AbMR) after kidney transplants. This study found increased levels in AbMR patients, unlike complement-coated microvesicles which were decreased.
Area of Science:
- Immunology
- Transplantation Medicine
- Biomarker Discovery
Background:
- Antibody-mediated rejection (AbMR) is a major cause of kidney transplant failure.
- Current diagnosis relies on invasive kidney biopsies and C4d deposition detection.
- Soluble complement fragments and microvesicles are potential non-invasive biomarkers.
Purpose of the Study:
- To investigate if soluble complement fragments or complement-bound microvesicles can non-invasively detect AbMR.
- To analyze complement activation markers in an in vitro model and in kidney transplant recipients.
Main Methods:
- Developed an in vitro model using human endothelial cells exposed to anti-HLA antibodies and complement.
- Measured soluble complement fragments (C4a, sC5b-9) and microvesicles in cell supernatants.
- Quantified plasma levels of complement fragments (C4a, Ba) and endothelial microvesicles in kidney transplant recipients with and without AbMR.
Main Results:
- In vitro, C4a and sC5b-9 increased in supernatants with complement activation.
- Microvesicles bearing C4 and C3 fragments were released from activated endothelial cells.
- Plasma C4a and Ba were significantly elevated in kidney transplant recipients with AbMR.
- Endothelial microvesicle counts were not increased; complement-opsonized microvesicles were decreased in AbMR patients.
Conclusions:
- Plasma complement activation fragments (C4a, Ba) show promise as non-invasive biomarkers for AbMR.
- Complement-opsonized endothelial microvesicles may be cleared more rapidly in AbMR patients.
- These findings suggest a potential shift towards non-invasive AbMR detection using soluble biomarkers.
Abstract:
Antibody-mediated rejection (AbMR) adversely affects long-term graft survival in kidney transplantation. Currently, the diagnosis of AbMR requires a kidney biopsy, and detection of complement C4d deposition in the allograft is one of the diagnostic criteria. Complement activation also generates several soluble fragments which could potentially provide non-invasive biomarkers of the process. Furthermore, microvesicles released into the plasma from injured cells can serve as biomarkers of vascular injury. To explore whether soluble complement fragments or complement fragments bound to endothelial microvesicles can be used to non-invasively detect AbMR, we developed an in vitro model in which human endothelial cells were exposed to anti-HLA antibodies and complement sufficient serum. We found that complement fragments C4a and sC5b-9 were increased in the supernatants of cells exposed to complement-sufficient serum compared to cells treated complement-deficient serum. Furthermore, complement activation on the cell surface was associated with the release of microvesicles bearing C4 and C3 fragments. We next measured these analytes in plasma from kidney transplant recipients with biopsy-proven acute AbMR (n = 9) and compared the results with those from transplant recipients who also had impaired allograft function but who did not have AbMR (n = 30). Consistent with the in vitro results, complement fragments C4a and Ba were increased in plasma from patients with AbMR compared to control subjects (P < 0.001 and P < 0.01, respectively). Endothelial microvesicle counts were not increased in patients with AbMR, however, and the number of microvesicles with C4 and C3 bound to the surface was actually lower compared to control subjects (both P < 0.05). Our results suggest that plasma complement activation fragments may be useful as non-invasive biomarkers of antibody-mediated complement activation within the allograft. Complement-opsonized endothelial microvesicles are decreased in patients with AbMR, possibly due to enhanced clearance of microvesicles opsonized with C3 and C4 fragments.
Related Concept Videos
Complement System
Antibody Actions
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...

